Drug Trial Radar · NCT03667716
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
Last checked: Nov 19, 2026Latest source record: Jan 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
121
Actual
Start
Sep 6, 2018
Primary completion
Jan 30, 2024
Study completion Jan 30, 2024
Sponsor
- Lead sponsor
- Compugen LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Bristol-Myers Squibb
- First posted
- Sep 12, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary clinical activity of COM701 as monotherapy and in combination with nivolumab.
Conditions
- Advanced Cancer
- Ovarian Cancer
- Breast Cancer
- Lung Cancer
- Endometrial Cancer
- Ovarian Neoplasm
- Triple Negative Breast Cancer
- Lung Neoplasm
- Neoplasm Malignant
- Colo-rectal Cancer
Interventions
COM701Drug
COM701 monotherapy.
COM701 with Opdivo (Nivolumab).Drug
COM701 in combination with Opdivo (Nivolumab).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of subjects with Adverse Events (AEs) as per CTCAE v4.03 and Dose-Limiting Toxicities (DLTs).Time frame: DLT evaluation window in the 1st cycle (21 or 28 days).
- Determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RDFE) (COM701 monotherapy and in combination with nivolumab).Time frame: Approximately 2 year.
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
University of California Los Angeles (UCLA).
Los Angeles, California
Florida Cancer Specialists
Sarasota, Florida
University of Chicago Medical Center
Chicago, Illinois
Massachusetts General Hospital
Boston, Massachusetts
START Midwest.
Grand Rapids, Michigan
Columbia University
New York, New York
Cleveland Clinic.
Cleveland, Ohio
The University of Tennessee WEST Cancer Center.
Memphis, Tennessee
Sarah Cannon Research Institute.
Nashville, Tennessee
M D Anderson Cancer Center.
Houston, Texas
The START Center for Cancer Care.
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.